Crowdsourcing pharmacogenomic data analysis: PGRN-Sage RA Responder Challenge PGRN Spring Meeting April 30, 2013 HARVARD MEDICAL SCHOOL.

Slides:



Advertisements
Similar presentations
Translating Science into Improved Health Care: Cancer as a Model William S. Dalton, Ph.D., M.D. Center Director H. Lee Moffitt Cancer Center & Research.
Advertisements

A centre of expertise in digital information management UKOLN is supported by: Open Science at Genome Scale Dr Liz Lyon, Director, UKOLN,
Miami CTSI--Culturalized Health Sciences for a Healthier South Florida! Clinical & Translational Science Institutes The U.S.A. launches an initiative to.
NHLBI Strategic Visioning Process: Charting Our Future Together
Michel Goldman, Executive Director Innovative Medicines Initiative (IMI)
The Open Innovation Center Susie Stephens, Principal Research Scientist, Eli Lilly.
Maryam Nazir. Personal Genomics:  Branch of genomics concerned with the sequencing and analysis of the genome of an individual  Once sequenced, it can.
Genetic Analysis in Human Disease
Influencing Change in Research, Treatment Protocols, and New Drug Development.
Alzheimer’s Disease Neuroimaging Initiative STEERING COMMITTEE April
Personalized Medicine
Survey of approval processes for HRECs at University of Melbourne affiliated hospitals (The SHREC Study) Professor David Story MBBS, MD, BMedSci, FANZCA.
Identifying RA patients from the electronic medical records at Partners HealthCare Robert Plenge, M.D., Ph.D. VA Hospital July 20, 2010 HARVARD MEDICAL.
Discovery of new medicines through new models of collaboration Simon Ward Professor of Medicinal Chemistry & Director of Translational Drug Discovery Group.
Metastatic Breast Cancer: One Size Does Not Fit All Clifford Hudis, M.D. Chief, Breast Cancer Medicine Service MSKCC.
Research Bioethics Consultation: More potential than sequencing genomes Benjamin S. Wilfond MD Seattle Children’s Hospital Treuman Katz Center for Pediatric.
Pharmacogenomics: Implications for CNS Drug Development in the 21st Century Challenges for Development & Approval – Patient & Funding Agency Perspective.
Elizabeth Karlson, MD Associate Professor of Medicine
Precision Medicine- Optimizing Patient Selection Janet Woodcock- “ How can we apply modern tools? ” Mark Rogge- “We need to understand the patients” Participant-Centered.
A crowdsourcing effort that poses questions (Challenges) about biology, modeling and data analysis: – Transcriptional networks.
Working across sectors Building collaborative eco-systems Lars Sundstrom SARTRE.
Leveraging Patient Engagement & the Role of Advocacy.
LARA MANGRAVITE SAGE BIONETWORKS ON BEHALF OF THE RA CHALLENGE ORGANIZING TEAM The DREAM Rheumatoid Arthritis Responder Challenge: Motivation, Data, Scoring.
Diabetes Clinical and Translational Research: Rewards and Challenges Ruth S. Weinstock MD PhD Medical Director, Joslin Diabetes Center and Clinical Research.
Sage Bionetworks Mission Sage Bionetworks is a non-profit organization with a vision to create a “commons” where integrative bionetworks are evolved by.
Should individuals be able to directly access their genetic information without physician involvement? Jeff Gulcher MD PhD Chief Scientific Officer and.
EPSA GSK Training on Soft Skills. B C Key Findings Results Research Process A.
A centre of expertise in digital information management UKOLN is supported by: Monica Duke Project.
Indiana Institute For Personalized Medicine David A Flockhart MD, PhD Professor of Medicine, Genetics and Pharmacology Indiana University.
Sage Bionetworks A non-profit organization with a vision to enable networked team approaches to building better models of disease BIOMEDICINE INFORMATION.
How can we work together? Partnering with Industry: An Investigator’s Perspective Robert L. Coleman, MD M. D. Anderson Cancer Center.
National Heart, Lung, and Blood Institute Women’s Health Initiative Branch Jacques Rossouw, MD Chief, WHI Branch Program for Prevention and Population.
Christina Leslie, Lonnie Welch, Chairs Gustavo Stolovitzky, Chair Andrea Califano, Chair Steven Leard, Chris Williams Manolis Kellis, Chair Alex Pico,
The Value of Tissue Banks to Drug and Dx Developers Barbara L. Handelin, Ph.D. Conflicts of Interest, Privacy/Confidentiality, and Tissue Repositories:
Single Patient Use of Investigational Anticancer Agents: An Industry Perspective Gerard T. Kennealey, MD Vice President, Clinical Research, Oncology AstraZeneca.
Sage / DREAM Breast Cancer Prognosis Challenge The goal of the breast cancer prognosis challenge is to assess the accuracy of computational models designed.
Personalized Medicine Dr. M. Jawad Hassan. Personalized Medicine Human Genome and SNPs What is personalized medicine? Pharmacogenetics Case study – warfarin.
Adam Heathfield, PhD Senior Director, Worldwide Policy, Pfizer Inc. September 25, 2013 Personalised Medicine – an industry perspective.
PUTTING THE PATIENT AT THE CENTER OF HEALTHCARE RESEARCH Towards a more inclusive model.
Wisconsin Genomics Initiative W isconsin M edical R esearch T riangle Wisconsin Medical Discovery Triangle.
Sage Bionetworks A non-profit organization with a vision to enable networked team approaches to building better models of disease BIOMEDICINE INFORMATION.
Using Predictive Classifiers in the Design of Phase III Clinical Trials Richard Simon, D.Sc. Chief, Biometric Research Branch National Cancer Institute.
Sage Bionetworks Mission Sage Bionetworks is a non-profit organization with a vision to create a “commons” where integrative bionetworks are evolved by.
Privacy Symposium / HIPAA Summit
Miriam Evans International Niemann Pick Disease Alliance (INPDA) Contact: Tel: +44 (0) #raredisease Patient involvement.
Why Write A Grant? Elaine M. Hylek, MD, MPH Professor of Medicine Associate Director, Education and Training Division BU CTSI Section of General Internal.
D4FF55A0-6B6F BF422A9BA9 Present by: Xiao Chen On December 7, 2015.
Kathleen Giacomini, Mark J. Ratain, Michiaki Kubo, Naoyuki Kamatani, and Yusuke Nakamura NIH Pharmacogenomics Research Network III & RIKEN Center for Genomic.
NIAMS Extramural Scientific Planning Retreat 2013 April 4, 2013 Session 1: Strategies for Successful Rare Disease Clinical Trials.
Clinical and Translational Science Awards (CTSAs) Future Directions and Opportunities for ACNP investigators.
Patient Engagement throughout the Biopharmaceutical Lifecycle: Tips for Effective Patient Advocate/Industry Collaboration to Improve Patient Access and.
The opportunities and challenges of sharing genomics data with the pharmaceutical industry Shahid Hanif, Head of Health Data & Outcomes, ABPI DNA digest.
A Genomics-Enabled Rapid Learning Health System Goals for 2015 & 2016 Lynn Etheredge IOM – December 8, 2014.
European Patients’ Academy on Therapeutic Innovation Challenges in Personalised Medicine.
TITIN ANDRI WIHASTUTI SCHOOL OF NURSING FACULTY OF MEDICINE
Big Data Analyses: The Cancer Moonshot
Trial Innovation Network Uncovering Grand Opportunities
Dept of Biomedical Informatics University of Pittsburgh
Knowledge l Action l Impact
Health Disparities in the Era of Precision Medicine
Optimizing Patient Outcomes in IBD
Wisconsin Genomics Initiative
EULAR Study Group on Registers and Observational Drug Studies (RODS)
Clinical and Translational Science Awards Program
Getting to Grips With the Science of CGRP and Migraine
AACR Project GENIE at a glance.
Incidence rates of hospitalised infection per 100 person-years, standardised for age and sex, among patients with RA from five RA registries and one RA.
Patient Heterogeneity in CD
Meet the JAKs.
Vylyny Chat, Robert Ferguson, Tomas Kirchhoff 
Presentation transcript:

Crowdsourcing pharmacogenomic data analysis: PGRN-Sage RA Responder Challenge PGRN Spring Meeting April 30, 2013 HARVARD MEDICAL SCHOOL

Predicting response in RA N=2,700 RA patients

GWAS (n=2,700) GWAS (n=2,700) How our data are silo’d

GWAS (n=2,700) GWAS (n=2,700) How our data are silo’d

The power of the crowd…

Crowdsourcing is not a new idea…

Crowdsourcing today is widely used

Engage large group of participants –Beyond our immediate collaborators Open dialogue on methods and results –Rapid-learning, with insights in real-time Facilitate peer-review –Challenge-assisted vs traditional peer- review Benefits of crowdsourcing Plenge et al Nature Genetics 2013

How can we effectively use crowdsourcing for PGx traits?

Define a discrete biological questions –Polygenic predictor of response to anti-TNF therapy in rheumatoid arthritis Assemble unique datasets –Discovery GWAS (n=2,700 RA patients) –Validation GWAS (n=1,100 RA patients)*** –Additional genomic data (RNA-seq, etc) Partner with group to host Challenge –Sage-DREAM Assemble teams to compete –Any group with IRB approval! RA Responder Challenge *** RIKEN application pending

RA Responder Challenge Discovery (phase I) GWAS of treatment response in RA (n≈2,700 patients) GWAS of treatment response in RA (n≈2,700 patients) Genomic data (e.g., expression profiling) Genomic data (e.g., expression profiling) Polygenic SNP predictor of response What is the best SNP- based genetic model to predict response to anti- TNF therapy in RA? Polygenic modeling project Eli Stahl Sarah Pendergrass Marylyn Ritchie Jing Cui

RA Responder Challenge Discovery (phase I) GWAS of treatment response in RA (n≈2,700 patients) GWAS of treatment response in RA (n≈2,700 patients) Genomic data (e.g., expression profiling) Genomic data (e.g., expression profiling) Polygenic SNP predictor of response *** An outcome of the PGRN polygenic modeling network-wide project

RA Responder Challenge Discovery (phase I) GWAS of treatment response in RA (n≈2,700 patients) GWAS of treatment response in RA (n≈2,700 patients) Genomic data (e.g., expression profiling) Genomic data (e.g., expression profiling) Polygenic SNP predictor of response Refine model Open Collaboration Peer insights 1) 2) etc. Peer insights 1) 2) etc. synapse Build models as a community, sharing insights in real-time Sage Bionetworks Lara Mangravite Jonathan Derry Stephen Friend

RA Responder Challenge Discovery (phase I) Validation (phase II) GWAS of treatment response in RA (n≈2,700 patients) GWAS of treatment response in RA (n≈2,700 patients) Genomic data (e.g., expression profiling) Genomic data (e.g., expression profiling) Polygenic SNP predictor of response Refine model Open Collaboration Peer insights 1) 2) etc. Peer insights 1) 2) etc. Submit models GWAS of treatment response in RA (n≈1,100 patients) GWAS of treatment response in RA (n≈1,100 patients) Score models synapse Test models in an independent dataset (CORRONA) CORRONA Jeff Greenberg Dimitrios Pappas Joel Kremer

RA Responder Challenge Discovery (phase I) Validation (phase II) GWAS of treatment response in RA (n≈2,700 patients) GWAS of treatment response in RA (n≈2,700 patients) Genomic data (e.g., expression profiling) Genomic data (e.g., expression profiling) Polygenic SNP predictor of response Refine model Open Collaboration Peer insights 1) 2) etc. Peer insights 1) 2) etc. Challenge-assisted peer review Submit models GWAS of treatment response in RA (n≈1,100 patients) GWAS of treatment response in RA (n≈1,100 patients) Score models Publication peer review synapse Peer-review responses Publication Publish with Nature Genetics

Scientific –What is the power to detect polygenic signal? –How much will genomic datasets add? –Is a SNP-based approach the best? Social –Will groups collaborate or compete? –Is the Synapse platform sufficient to communicate among diverse groups? Practical –How will we manage data access? Unresolved questions of our crowdsourcing approach

Industry sponsorship –Several companies have promised support to host the Challenge –Initial conversations to generate more data Foundation sponorship –Arthritis Foundation has supported the Challenge, given next-gen approach and “citizen-scientist” emphasis Sharing among colleagues –no issues sharing data…actually more! Initial surprises from putting the Challenge together

RNA-predictors of response Internet registry “citizen-scientist” clinical trial NIH academic-industry “target validation consortium” –“disease deconstruction” This is meant to be the first step

Sage-DREAM collaboration Breast Cancer Challenge –Published in Science Translational Medicine Glioblastoma Challenge Other Challenges planned for 2013 –See sagebase.org for list of Challeges

Is crowdsourcing attractive to other PGRN investigators?